| Pfizer says EU recommends approval of Inlyta - NECN |
|
|
NECN A European Union advisory committee recommended that Inlyta be approved as a treatment for advanced renal cell carcinoma in patients who were not helped by treatment with Pfizer's drug Sutent or with cytokines, a class of cancer medications that are no |